Stage- and CA125–related survival in patients with epithelial ovarian cancer treated at a cancer center

Authors

  • R.E. BOARD,

    Corresponding author
    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • C.T.P.H. BRUIJNS,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • A.E. PRONK,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • W.D.J. RYDER,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • P.M. WILKINSON,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • R. WELCH,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • J.H. SHANKS,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • G. CONNOLLY,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • R.J. SLADE,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • K. REYNOLDS,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • H.C. KITCHENER,

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author
  • G.C. JAYSON

    1. *Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
    Search for more papers by this author

Address correspondence and reprint requests to: Dr Ruth Board, BSc, MBChB, Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK. Email: ruth.board@christie-tr.nwest.nhs.uk

Abstract

Abstract.  Board RE, Bruijns CTPH, Pronk AE, Ryder WDJ, Wilkinson PM, Welch R, Shanks JH, Connolly G, Slade RJ, Reynolds K, Kitchener HC, Jayson GC. Stage- and CA125–related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer 2006;16(Suppl. 1):18–24.

Current accepted prognostic indicators in ovarian cancer include performance status, surgical (FIGO) staging, and residual disease after operation. Here we present data from a prospective analysis of patients with ovarian cancer treated at the Christie Hospital. We confirm the independent prognostic effects of FIGO staging, performance status, and residual disease in our group of patients and furthermore show that CA125 levels at presentation to the oncology service are of independent prognostic significance (P= 0.02). We present survival data and show that the 3-year, cancer-specific survival for stage I disease is 90%. We postulate that this good survival may in part be due to the use of computed tomography scanning at presentation to allow accurate staging. Further clinical trials are needed to test whether combinations of surgical, histologic, biochemical, and radiologic parameters can be used to identify a population with such a good prognosis that adjuvant therapy is not required.

Ancillary